Drug Type Small molecule drug |
Synonyms NBTX 001, NBTX001 |
Target |
Action antagonists |
Mechanism NMDA receptor antagonists(Glutamate [NMDA] receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Stress Disorders, Post-Traumatic | Phase 3 | - | 01 Jun 2021 | |
| Anxiety Disorders | Phase 1 | Russia | 15 Dec 2019 | |
| Parkinson Disease | Phase 1 | Russia | 15 Dec 2019 | |
| Panic Disorder | Phase 1 | Russia | - | |
| Obsessive-Compulsive Disorder | Preclinical | United States | 24 Nov 2023 | |
| Autism Spectrum Disorder | Preclinical | United States | 09 Apr 2018 | |
| Irritable Bowel Syndrome | Preclinical | United States | 12 Mar 2018 | |
| Alzheimer Disease | Preclinical | United States | 07 Mar 2018 |





